>Go!
NEWS SEARCH

09.08.2017 | Investors

Pro Football Hall of Famer Deion Sanders Tackles Frown Lines And Crow's Feet With BOTOX® Cosmetic (onabotulinumtoxinA)1

Iconic Athlete and Sports Commentator Tells Men That BOTOX® Cosmetic Isn't Just for Women

DUBLIN, Sept. 8, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that NFL analyst and philanthropist, Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, will serve as a brand ambassador for BOTOX® Cosmetic.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8174251-allergan-deion-sanders-botox/

Harnessing Sanders' trademark swagger, style and humor, Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow's feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well.

"I've always taken pride in my appearance. Turning 50 prompted me to take an honest look in the mirror. When I did, I noticed lines between my brows and in the corners of my eyes - and that's just not Prime," said Sanders. "So that's why I'm telling men that if they're like me, and don't like seeing frown lines and crow's feet, they should talk to a doctor. I did, and with his help, made the choice to get treated with BOTOX® Cosmetic."1

BOTOX® Cosmetic helped launch the aesthetic market with its first FDA approval in 2002 for the temporary improvement in the look of moderate to severe glabellar lines (wrinkles between the eyebrows, known as frown lines), in adults. In 2013, BOTOX® Cosmetic was approved to temporarily improve the look of moderate to severe crow's feet lines in adults, making it the only FDA-approved treatment to temporarily improve both moderate to severe crow's feet and frown lines.1

And Sanders isn't the only man prioritizing his appearance. The male aesthetic market has seen steady, but quiet growth, with more men choosing treatment.2 Allergan's partnership with Sanders is the culmination of the company's mission to get men talking about aesthetics.

"We know the male aesthetic market is an area of great opportunity, but despite the increasing demand, there is a lack of open dialogue among men about aesthetic treatments and concerns," said David Moatazedi, Senior Vice President, US Medical Aesthetics. "Deion Sanders is the perfect partner to help us reach and mobilize men. He shares our philosophy that it's acceptable for a man to invest in his appearance and has the confidence to ignite this important, and long overdue, conversation."

Allergan takes pride in its commitment to the quality of its products and BOTOX® Cosmetic is the most widely researched and studied treatments of its kind, with ~16 years of data from clinical studies.3 The safety and efficacy has been evaluated in Allergan clinical studies and described in more than 440 peer-reviewed articles in scientific and medical journals.4 For more information about BOTOX® Cosmetic please visit: www.BOTOXCosmetic.com/men

IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing

BOTOX® Cosmetic dosing Units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, or both at the same time.

BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not take BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.

Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; weakness of forehead muscles: trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal products. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

Other side effects of BOTOX® Cosmetic include: discomfort or pain at the injection site; headache; and eye problems: double vision, blurred vision, drooping eyelids, and swelling of your eyelids.

For more information refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan at 1-800-433-8871.

Please see BOTOX® Cosmetic full Product Information including Boxed Warning and Medication Guide. 

References:
1. BOTOX® Cosmetic Prescribing Information, 2017.
2. Data on File, Allergan; Dosing Records Study Male Patient Profile, 2016.
3. Data on File, Allergan; Patient Clinicals.
4. Data on File Allergan; Peer-Reviewed Articles.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.

 

CONTACTS:

Allergan:


Investors:


Daphne Karydas


(862) 261-8006



Media:


Mark Marmur


(862) 261-7558



Ember Garrett


(714) 246-3525

 

 

Allergan plc logo

 

View original content:http://www.prnewswire.com/news-releases/pro-football-hall-of-famer-deion-sanders-tackles-frown-lines-and-crows-feet-with-botox-cosmetic-onabotulinumtoxina1-300515883.html

SOURCE Allergan plc

Media Contacts
Mark Marmur
Global Corporate Media Relations
+1 (862) 261 7558
Fran DeSena
U.S. Product Media Relations
+1 (201) 427-8762
Janet Kettels
International Product Media Relations
+44 773 850 6476

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Karina Calzadilla
Investor Relations
+1 (862) 261 7488